)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ImmuCell
ImmuCell (ICCC) investor relations material
ImmuCell Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Revenue for Q2 2026 increased 11.5% year-over-year to $7.2 million, driven by higher sales volumes, price increases, and strong demand for First Defense®, with expanded market share and investments in leadership, sales, and manufacturing.
Net income for Q2 2026 rose to $1.8 million (25.5% margin), up from $0.5 million, aided by a $2 million legal settlement from a former contract manufacturer.
Distributor out-the-door volume grew 28% in Q2 2026, with Tri-Shield® and Functional Feed lines contributing to growth.
Commercial results benefited from restored product availability, expanded commercial team, and favorable domestic calf market conditions.
The company is executing a two-phase manufacturing expansion to triple capacity, with $8 million in planned investments over 18 months.
Financial highlights
Six-month revenue increased 20.9% year-over-year to $17.5 million; Q2 2026 product sales were $7.2 million, up from $6.4 million.
Gross margin declined to 33.9% from 43.7% in Q2 2025, mainly due to higher costs, lower output, and cost shifts.
Net income for the first six months was $3.8 million, nearly doubling year-over-year.
Adjusted EBITDA for Q2 2026 was $2.7 million, up from $1.4 million; six-month adjusted EBITDA was $5.4 million.
Cash and cash equivalents increased to $8.9 million as of June 30, 2026, from $3.8 million at year-end 2025; stockholders’ equity rose to $31.4 million.
Outlook and guidance
Capacity expansion projects totaling $8 million are expected to be completed in phases through 2027, aiming to triple capacity and improve costs.
Focus on yield improvement, cost management, and reliable supply to support scalable growth.
Ongoing investments in manufacturing are expected to support future demand growth for First Defense®.
No pending plans to issue additional shares under the ATM equity program as of June 30, 2026.
The company anticipates continued tax liability as NOLs now offset only 80% of taxable income.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImmuCell
- Strong growth, market share gains, and financial recovery position First Defense® for expansion.ICCC
Investor presentation - Record sales and margin growth position First Defense® for continued market share gains.ICCCInvestor presentation
- All proposals passed and a major manufacturing expansion was announced to support growth.ICCCAGM 2026
- First Defense® gains share in a growing market, fueling record sales and margin expansion.ICCCInvestor presentation
- Record Q1 2026 sales and net income growth fueled by margin gains and strong cash flow.ICCCQ1 2026
- Shareholders will vote on board elections, compensation, new equity plan, officer exculpation, and auditor approval.ICCCProxy filing
- Double-digit growth, rising market share, and financial recovery fuel expansion in scours prevention.ICCCInvestor presentation
- Full-year sales up 4.3% as Tri-Shield® growth and First Defense® focus offset declines.ICCCQ4 2025 TU
- Record Q1 sales, margin gains, and net income highlight strong growth and operational recovery.ICCCQ1 2025
Next ImmuCell earnings date
Q3 202613 Nov, 2026
ImmuCell
Next ImmuCell earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ImmuCell Corporation, an animal health company, designs, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle worldwide. It focuses on developing products that improve the health of calves during the period from birth through weaning.